TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25078041

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) insufflation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Room air insufflation
Number of subjects: 0
Study: 23070151

Group type: EXPERIMENTAL
Intervention: IDX184 25 mg once daily for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IDX184 50 mg once daily for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IDX184 75 mg once daily for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: IDX184 100 mg once daily for 3 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 20518809

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Calculated LDL variability
Number of subjects: 26
Study: 17961729

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study: 15674510

Group type: EXPERIMENTAL
Intervention: Landiolol 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Landiolol 10 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 36
Study: 12059867

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (Pilocarpine only)
Number of subjects: 47
Study: 9587773

Group type: EXPERIMENTAL
Intervention: Haloperidol + Carbamazepine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 18
Study: 7832389

Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 52
Study: 2227553

Group type: EXPERIMENTAL
Intervention: Chemotherapy (3 additional courses)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Radiotherapy (whole-abdomen)
Number of subjects: 41
Study: 89390

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ergotamine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30795782

Group type: EXPERIMENTAL
Intervention: Intravascular cooling (IC)
Number of subjects: 352
Study: 28087382

Group type: EXPERIMENTAL
Intervention: Egg rush oral immunotherapy (ROIT) in ROIT1 group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Egg rush oral immunotherapy (ROIT) in ROIT2 group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Adverse events during the build-up phase
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Skin prick test, specific IgE, and specific IgE/IgG4 ratio to egg fractions
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Specific IgG4 levels
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study: 26043229

Group type: EXPERIMENTAL
Intervention: TT genotype (risk allele)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CC genotype (common allele)
Number of subjects: 14
Study: 23311856

Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual and Customary Therapy of Equivalent Dose (DEUCC)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual and Customary Therapy (UCC)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Active Monitoring Only (UCC)
Number of subjects: 360
Study: 21704786

Group type: EXPERIMENTAL
Intervention: Structured home-based exercise program
Number of subjects: 142

Group type: COMPARATOR
Intervention: Supervised exercise training (SET)
Number of subjects: 142
Study: 19749490

Group type: EXPERIMENTAL
Intervention: Exercise training (70 min, 2 times per week for 12 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no exercise training, received exercise advice at baseline)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 53
Study: 16473722

Group type: EXPERIMENTAL
Intervention: Halogen light with a 20-second curing time
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plasma arc light with 2-second curing time
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plasma arc light with 6-second curing time
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Plasma arc light with 10-second curing time
Number of subjects: 90

Group type: COMPARATOR
Intervention: Halogen light and Plasma arc light
Number of subjects: 90
Study: 15078377

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (1 mg/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg)
Number of subjects: 57
Study: 11200732

Group type: EXPERIMENTAL
Intervention: Close follow‐up group (CFG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone follow‐up group (TFG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mail follow‐up group (MFG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health diaries
Number of subjects: 0
Study: 9060567

Group type: EXPERIMENTAL
Intervention: Sucralfate solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Number of subjects: 131
Study: 8326220

Group type: EXPERIMENTAL
Intervention: Anterior inferior turbinoplasty
Number of subjects: 80

Group type: COMPARATOR
Intervention: No anterior inferior turbinoplasty (non-turbinectomy group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Turbinate reduction in patients with less pronounced septal deviation
Number of subjects: 80
Study: 2868162

Group type: EXPERIMENTAL
Intervention: tamoxifen 20 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 31916941

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 45

Group type: COMPARATOR
Intervention: Direct laryngoscope
Number of subjects: 45
Study: 29431126

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham rTMS treatment (Control)
Number of subjects: 66
Study: 26476022

Group type: EXPERIMENTAL
Intervention: IV tissue plasminogen activator (tPA) alone
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: IV tPA + endovascular therapy (Solitaire stent-retriever)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Union of baseline core and early follow-up Tmax > 6-second volume
Number of subjects: 151
Study: 25174240

Group type: EXPERIMENTAL
Intervention: Spanish video explaining the risks and benefits of anesthesia
Number of subjects: 2

Group type: COMPARATOR
Intervention: Non-video group
Number of subjects: 2
Study: 22341554

Group type: EXPERIMENTAL
Intervention: 2-session intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Assessment-only condition (AO)
Number of subjects: 48
Study: 19672742

Group type: EXPERIMENTAL
Intervention: Treatment group II (oral compound calcium acid chelate, Vitamin AD guttate and ipriflavone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treatment group I (oral compound calcium acid chelate and Vitamin AD guttate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo and compound calcium acid chelate)
Number of subjects: 60
Study: 18782465

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin (n = 539)
Number of subjects: 768

Group type: COMPARATOR
Intervention: Simvastatin monotherapy (n = 229)
Number of subjects: 768
Study: 16184721

Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 3 times/day for 7 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (no Octreotide)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study: 12932593

Group type: EXPERIMENTAL
Intervention: Immediate stenting after thrombolysis (group I)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Delayed stenting after two weeks (group II)
Number of subjects: 197
Study: 10923997

Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no disulfiram)
Number of subjects: 36
Study: 8927315

Group type: EXPERIMENTAL
Intervention: Ciba Vision AOSept Disinfection/Neutralization Solutions (AOSept)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Opti‐Free Rinsing, Disinfection, and Storage Solution (Opti‐Free)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: ReNu Multi‐Purpose Solution (ReNu)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CibaSoft Visitint or CibaSoft‐Standard Visitint contact lenses
Number of subjects: 84
Study: 1520203

Group type: EXPERIMENTAL
Intervention: Clearplan home ovulation detection kits for 3 cycles
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (advised about optimal time during menstrual cycle)
Number of subjects: 148
Study: 6328637

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Cimetidine (1 g daily in divided doses)
Number of subjects: 339
Study: 31793630

Group type: EXPERIMENTAL
Intervention: Adalimumab combination therapy (34 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Adalimumab monotherapy (44 patients)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Adalimumab combination therapy and monotherapy
Number of subjects: 78
Study: 30912010

Group type: EXPERIMENTAL
Intervention: RT‐HIIT
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AT‐HIIT
Number of subjects: 240

Group type: COMPARATOR
Intervention: UC
Number of subjects: 240
Study: 29056106

Group type: EXPERIMENTAL
Intervention: High dietary calcium (547 mg DC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High supplemental calcium (500 mg SC-calcium carbonate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low calcium (42 mg DC)
Number of subjects: 16
Study: 27067867

Group type: EXPERIMENTAL
Intervention: Canine guided dentures
Number of subjects: 19

Group type: COMPARATOR
Intervention: Bilateral balanced occlusion dentures
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: New complete dentures (both occlusal concepts)
Number of subjects: 19
Study: 24355490

Group type: EXPERIMENTAL
Intervention: Real-time explanations for noncompliance
Number of subjects: 207
Study: 22607302

Group type: EXPERIMENTAL
Intervention: Smartphone-based behavioral activation intervention for 8 weeks with minimal therapist contact.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Attention control group with brief online education and a smartphone application not aimed at depression for 8 weeks.
Number of subjects: 120
Study: 19717844

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 18113

Group type: COMPARATOR
Intervention: Warfarin (adjusted-dose)
Number of subjects: 18113
Study: 17470687

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vatalanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy alone
Number of subjects: 0
Study: 15127068

Group type: EXPERIMENTAL
Intervention: Commonly used food models
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Larger-sized food models
Number of subjects: 50
Study: 12905875

Group type: EXPERIMENTAL
Intervention: Immune enhanced enteral nutrition (arginine, RNA, omega 3 fatty acid enriched)
Number of subjects: 120
Study: 9630386

Group type: EXPERIMENTAL
Intervention: Green tea (0.9 g total catechins)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Black tea (0.3 g total catechins)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Black tea with milk (100 ml in 600 ml)
Number of subjects: 12
Study: 7835196

Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 3135784

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) at 120% of resting energy expenditure (REE) with 0.2 g of N/kg/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) at 200% of resting energy expenditure (REE) with 0.33 g of N/kg/d
Number of subjects: 16
Study: 31394274

Group type: EXPERIMENTAL
Intervention: Flu-based conditioning (Flu1: Flu 120-150 mg/m2, Cy 120-200 mg/kg, ATG 20 mg/kg; Flu2: Flu 150 mg/m2, Cy 300 mg/m2, ATG 20 mg/kg)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Flu1 conditioning
Number of subjects: 147

Group type: COMPARATOR
Intervention: Flu2 conditioning
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Flu-based conditioning
Number of subjects: 147
Study: 28754566

Group type: EXPERIMENTAL
Intervention: Asymmetric dimethylarginine (ADMA) levels
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline FFR <0.90
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Baseline ADMA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dichotomized ADMA (≥0.60 µM)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ADMA
Number of subjects: 46
Study: 25050594

Group type: EXPERIMENTAL
Intervention: BDP/F‐HFA 100/6 μg pMDI
Number of subjects: 95

Group type: COMPARATOR
Intervention: Budesonide/formoterol 320/9 μg DPI
Number of subjects: 95

Group type: COMPARATOR
Intervention: Fluticasone/salmeterol 500/50 μg DPI
Number of subjects: 95
Study: 22210797

Group type: EXPERIMENTAL
Intervention: Behavior modification program using GPS vehicle tracking devices with contingency incentives and disincentives
Number of subjects: 6

Group type: COMPARATOR
Intervention: Baseline period (no treatment)
Number of subjects: 6
Study: 21350421

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 78

Group type: COMPARATOR
Intervention: Milgamma
Number of subjects: 78
Study: 19228428

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg, qid)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Prednisolone (30 mg once daily) plus inhaled formoterol (9 microg bid)
Number of subjects: 109
Study: 16402915

Group type: EXPERIMENTAL
Intervention: Milrinone (n=15) infusion for 72 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dobutamine (n=14) infusion for 72 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Short-term inotropic support (Milrinone or Dobutamine)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Patients with decompensated CHF before inotropic treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Age-matched healthy volunteers (n=15, 54.1±3.2 years)
Number of subjects: 29
Study: 15673102

Group type: EXPERIMENTAL
Intervention: Microhydrin (MH)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 7
Study: 12498742

Group type: EXPERIMENTAL
Intervention: Presentation of pleasant images
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Presentation of unpleasant images
Number of subjects: 16

Group type: COMPARATOR
Intervention: Neutral images (control)
Number of subjects: 16
Study: 9619473

Group type: EXPERIMENTAL
Intervention: Attentionally directed away from complaints during acquisition
Number of subjects: 56

Group type: COMPARATOR
Intervention: Not attentionally directed away from complaints during acquisition
Number of subjects: 56
Study: 8702068

Group type: EXPERIMENTAL
Intervention: Bionator treatment for an average of 18.7 months
Number of subjects: 60
Study: 2716625

Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol (Glaxo)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 200 micrograms of salbutamol sulphate (Riker)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400 micrograms of salbutamol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 400 micrograms of salbutamol sulphate
Number of subjects: 21
Study: 1233531

Group type: EXPERIMENTAL
Intervention: Low dosage of perphenacine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study: 31169924

Group type: EXPERIMENTAL
Intervention: Exercise training (ET; high-intensity interval training plus power training)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (CT; usual care)
Number of subjects: 29
Study: 27511956

Group type: EXPERIMENTAL
Intervention: Feeling of choice in taking on care responsibilities
Number of subjects: 1087

Group type: EXPERIMENTAL
Intervention: Prolonged caregiving and limited availability of accessible and affordable care services
Number of subjects: 1087
Study: 25443473

Group type: EXPERIMENTAL
Intervention: Parent Cystic Fibrosis Questionnaire‐‐Revised (CFQ‐R)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Treatment Burden scale
Number of subjects: 314
Study: 23136195

Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) plus mitoxantrone and prednisone (MP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rilotumumab (7.5 mg/kg) plus mitoxantrone and prednisone (MP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control (placebo) plus mitoxantrone and prednisone (MP)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg) and (7.5 mg/kg)
Number of subjects: 144
Study: 21756757

Group type: EXPERIMENTAL
Intervention: AZT + DDI + NVP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: D4T + 3TC + NVP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: AZT + 3TC + NVP
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: D4T or DDI
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: NVP-containing regimen
Number of subjects: 198
Study: 19469601

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Number of subjects: 40
Study: 16908789

Group type: COMPARATOR
Intervention: Varenicline 1.0 mg twice daily
Number of subjects: 518

Group type: COMPARATOR
Intervention: Varenicline 0.5 mg twice daily
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Varenicline (both doses)
Number of subjects: 518
Study: 15204455

Group type: EXPERIMENTAL
Intervention: Parental verbal contingencies for stuttering
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Parent severity ratings
Number of subjects: 38
Study: 11759177

Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (Liposom Forte) administered intramuscularly (2 ml every other day for 60 days)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Phospholipid liposomes (Liposom Forte) administered intramuscularly
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo administered intramuscularly
Number of subjects: 64
Study: 9160017

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Immediate pars plana vitrectomy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Tap-biopsy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Immediate vitrectomy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Factors other than treatment
Number of subjects: 129
Study: 8195354

Group type: EXPERIMENTAL
Intervention: Superovulation with pure follicle stimulating hormone (FSH)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (56 patients matched for age, category, and duration of infertility)
Number of subjects: 224
Study: 3073903

Group type: EXPERIMENTAL
Intervention: Monocomponent human insulin
Number of subjects: 138

Group type: COMPARATOR
Intervention: Monocomponent porcine insulin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 138
Study: 29939959

Group type: EXPERIMENTAL
Intervention: Hypnosis plus standard care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 62
Study: 28716454

Group type: COMPARATOR
Intervention: 2D mammography
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: 2D plus DBT
Number of subjects: 1227
Study: 25457116

Group type: EXPERIMENTAL
Intervention: Checklists
Number of subjects: 48
Study: 23132825

Group type: EXPERIMENTAL
Intervention: NT‐proBNP‐guided HF care
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard of care (SOC) management
Number of subjects: 151
Study: 21146930

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Active control procedure
Number of subjects: 177

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 177
Study: 18496949

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass surgery
Number of subjects: 10

Group type: COMPARATOR
Intervention: No EC‐IC bypass surgery
Number of subjects: 10
Study: 16458316

Group type: EXPERIMENTAL
Intervention: 1.5 g/day niacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12934974

Group type: EXPERIMENTAL
Intervention: Clozapine (N = 18)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Haloperidol decanoate (N = 26)
Number of subjects: 44
Study: 11123486

Group type: EXPERIMENTAL
Intervention: Baclofen (40 mg maximum daily dose, given three times a day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clonidine (0.8 mg maximum daily dose, given three times a day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 62
Study: 9387732

Group type: EXPERIMENTAL
Intervention: Injection Salviae Miltiorrhizae
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 53
Study: 1329920

Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated heparin 7500 I.U.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both Enoxaparin and UF heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who developed post-operative DVT
Number of subjects: 0
Study: 3883817

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Phenelzine and Amitriptyline
Number of subjects: 51
Study: 30428503

Group type: EXPERIMENTAL
Intervention: Exercise training with follow-up calls at home for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no exercise training or follow-up calls)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Exercise training with follow-up calls at home
Number of subjects: 62
Study: 30121453

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus all-trans retinoic acid (ATRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0